Genmab — April 2018

GeorgeBest

Genmab har allerede i slutningen af sidste år varslet en kraftig stigning i omkostninger p.g.a. øget investering i pipeline

GeorgeBest

Jan signalerede i forgårs at Genmab og SGEN var ved at opdele verden for salg af TV. Så det tyder på man selv vil sælge dette produkt. Men man må da håbe at sælgerne ikke ansætte før tv er godkendt

jkj

Virker mere som at den nedadgående trend skyldes af A/B er gået fra køb til salg, NBI er steget de sidste par dage på trods af DT.

E_L

Genmab seriously underperformed the rest of the market since the beginning of the month ; so i dont think it is either Trump or Jan…

E_L

It
could be positioning in front of the numbers next week, as mcjean stated.

E_L

It could also be a bit of technical trading; we hit 61.8 retracement on Mar 28 (28/3 16:01 af E L : let's hope we can deal with 1300 fast; it is the 61.8% retracement ) .

E_L

This morning we retraced 38.2% of the rally from 994.8 (at 1185) and 61.8% from the gap open at 1104 on Feb 22 (1180). That could be enough and it gives a solid bounce so far.

E_L

(For harmonic traders, this is enough for a Gartley to 1383 or a Bat to 1433)

E_L

or a could be something completely different that we dont know about

Mcjean

The rally will start monday i start bying monday:-)

Mcjean

So from 10.03,01 to 10.03,02 there will be a rally.

E_L

lol, but surely it will be massive, short but powerfull

Mcjean

Yep if the let me i buy all 200 at once, do you think its possible?:-D

E_L

oow, i dont know mcjean, you may have to split that order and divide it up over several banks

E_L

this Tisotumab Vedotin study - https://clinicaltrials.gov/ct2/history/NCT02001623?A=14&B=15&C=merged

; Status set to : Active, not recruiting , so i guess they are fully recruited , Enrollment: 170 instead of the 144 planned

E_L

Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab - https://onlinelibrary.wiley.com/doi/abs/10.1002/ccr3.1451

E_L

"The role of Daratumumab in this disease deserves further evaluation. " click on PDF for full text

E_L

Teaching Drugs New Tricks - https://www.project-syndicate.org/commentary/pharmaceutical-industry-repositioning-old-drugs-by-aris-persidis-and-andreas-persidis-2018-04 - mentioning the Arzerra story

Bulder

Interesting E L: Currently, there are no available data to suggest Daratumumab could cross the BBB; however, the fact that, the barrier can become more permeable in disease states and that there is no barrier in the meninges raises this possibility.

E_L

yes, and also interesting that she is currently on week 68 of treatment in a disease with a median overall survival of < 6 months